These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26367539)

  • 41. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
    Stewart HJ; Horne GA; Bastow S; Chevassut TJ
    Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of methyl isoxazoleazepines as inhibitors of BET.
    Hewitt MC; Leblanc Y; Gehling VS; Vaswani RG; Côté A; Nasveschuk CG; Taylor AM; Harmange JC; Audia JE; Pardo E; Cummings R; Joshi S; Sandy P; Mertz JA; Sims RJ; Bergeron L; Bryant BM; Bellon S; Poy F; Jayaram H; Tang Y; Albrecht BK
    Bioorg Med Chem Lett; 2015 May; 25(9):1842-8. PubMed ID: 25851940
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
    Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimization of a "bump-and-hole" approach to allele-selective BET bromodomain inhibition.
    Runcie AC; Zengerle M; Chan KH; Testa A; van Beurden L; Baud MGJ; Epemolu O; Ellis LCJ; Read KD; Coulthard V; Brien A; Ciulli A
    Chem Sci; 2018 Mar; 9(9):2452-2468. PubMed ID: 29732121
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds.
    Chan KH; Zengerle M; Testa A; Ciulli A
    J Med Chem; 2018 Jan; 61(2):504-513. PubMed ID: 28595007
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
    Puissant A; Frumm SM; Alexe G; Bassil CF; Qi J; Chanthery YH; Nekritz EA; Zeid R; Gustafson WC; Greninger P; Garnett MJ; McDermott U; Benes CH; Kung AL; Weiss WA; Bradner JE; Stegmaier K
    Cancer Discov; 2013 Mar; 3(3):308-23. PubMed ID: 23430699
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen.
    Ayoub AM; Hawk LML; Herzig RJ; Jiang J; Wisniewski AJ; Gee CT; Zhao P; Zhu JY; Berndt N; Offei-Addo NK; Scott TG; Qi J; Bradner JE; Ward TR; Schönbrunn E; Georg GI; Pomerantz WCK
    J Med Chem; 2017 Jun; 60(12):4805-4817. PubMed ID: 28535045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
    Ali I; Lee J; Go A; Choi G; Lee K
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4606-4613. PubMed ID: 28939121
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
    Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
    Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of Benzo[
    Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
    J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
    Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
    Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
    Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
    Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stereoselective synthesis of allele-specific BET inhibitors.
    Bond AG; Testa A; Ciulli A
    Org Biomol Chem; 2020 Oct; 18(38):7533-7539. PubMed ID: 32756710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.
    Wang Q; Li Y; Xu J; Wang Y; Leung EL; Liu L; Yao X
    Sci Rep; 2017 Aug; 7(1):8857. PubMed ID: 28821780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins.
    Fu Y; Zhang Y; Sun H
    Eur J Med Chem; 2021 Dec; 226():113853. PubMed ID: 34547507
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.